Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Compared with EGFR-mutant NSCLC, ROS1-rearranged tumors were more likely to exhibit imaging features of lymphangitic carcinomatosis (ROS1, 42%; EGFR, 12%; P < .01) and less likely to have air bronchograms in the primary tumor (ROS1, 2%; EGFR, 28%; P < .01). 31708389 2020
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE The safety-evaluable population for the safety analysis included all patients with ROS1 fusion-positive NSCLC in the three trials who received at least one dose of entrectinib (irrespective of dose or duration of follow-up). 31838015 2020
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Among 48 patients with ROS1-rearranged NSCLC enrolled in the METROS study, 20 (41.6%) of 48 had at least 1 VTE event. 31607443 2020
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Instead, co-targeting ROS1 and MEK may be an effective strategy for overcoming entrectinib resistance in ROS1-rearranged NSCLC. 31124056 2020
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Here we present the evidence concerning entrectinib, an ALK/ROS1/NTRK inhibitor developed across different tumor types harboring rearrangements in these genes, in the context of ROS1-driven NSCLC. 31572036 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Reflex simultaneous genotypic screening for EGFR by peptide nucleic acid clamping, and ALK and ROS1 by fluorescence in situ hybridization (FISH) was performed on consecutive NSCLC cases at the time of initial pathologic diagnosis. 30475455 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Lorlatinib is an oral small molecule inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer (NSCLC). 30604291 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Both <i>in vivo</i> and <i>in vitro</i> studies verified that butein exerted anti-NSCLC effect through activating endoplasmic reticulum (ER) stress-dependent reactive oxygen species (ROS) generation. 31360107 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 GeneticVariation disease BEFREE We identified 453 patients who had NSCLC with an oncogenic alteration in ALK receptor tyrosine kinase gene (ALK), ROS1, or MET proto-oncogene, receptor tyrosine kinase gene (MET) and were treated with crizotinib (11 with and 442 without prior ICI therapy). 30205166 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE We conducted a multi-institutional prospective study including consecutive EGFR, ALK, or ROS1-altered NSCLC patients with TKI resistance from 12 Spanish institutions. 31319999 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE In summary, better understanding the high incidence of CNS metastasis in ROS1+ NSCLC patients, how certain ROS1 fusion variant may increase the incidence of CNS metastasis, and any intra-cranial efficacy data of pemetrexed in ROS1+ NSCLC are all urgently needed. 30885345 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 GeneticVariation disease BEFREE We firstly identified ROS1-ADGRG6 fusion variant in NSCLC by NGS, which should be considered in further ROS1 detecting assays. 31382924 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients with ROS1-rearranged advanced NSCLC from PROFILE 1001. 30980071 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 GeneticVariation disease BEFREE These results demonstrated how the mutated residues tune the crizotinib response and may assist kinase inhibitor development especially for ALK G1202R, analogous to the ROS1 G2302R and MET G1163R mutations that are also resistant to crizotinib treatment in NSCLC. 31388026 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 GeneticVariation disease BEFREE Crizotinib is a standard treatment for advanced anaplastic lymphoma kinase (ALK)- or ROS1-fusion-gene-positive non-small cell lung cancer; however, serious adverse events (AEs), including elevated alanine aminotransferase (ALT)/aspartate aminotransferase (AST) and interstitial lung disease (ILD), develop occasionally. 30642448 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 GeneticVariation disease BEFREE <i>ROS1</i> rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) targeting <i>ROS1/MET/ALK</i> rearrangements. 30940295 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE We review the tissue requirements for ROS1 testing by immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) and we present a testing algorithm for advanced NSCLC and consider how the future of pathology testing for ROS1 may evolve. 31668406 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE Entrectinib is also under regulatory review in the USA (PDUFA date 18 August 2019) and EU [Priority Medicines (PRIME) designation] for NTRK-positive solid tumours and ROS1-positive NSCLC. 31372957 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE In this review, we discuss ROS1 rearrangements in non-small cell lung cancer, and provide an update on targeting ROS1-rearranged non-small cell lung cancer with crizotinib and newer generation tyrosine kinase inhibitors. 31313100 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE We performed a comprehensive analysis of METex14 in 414 EGFR/KRAS/ALK/ROS1-negative (quadruple negative) surgically resected NSCLCs. 30391211 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 GeneticVariation disease BEFREE Non-small-cell lung cancer (NSCLC) has various driver mechanisms, including ROS1 rearrangement with different fusion patterns. 30797499 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE In univariate analysis, the odds of a TEE in ROS1+ NSCLC were higher than ALK+, EGFR+, and KRAS+ cohorts. 30543838 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 AlteredExpression disease BEFREE In addition, messenger RNA transcripts including EGFR, KRAS, ALK, MET, LKB1, BRAF, PIK3CA, RET, and ROS1 were significantly higher expressed in lung EVs in smokers and NSCLC patients compared to controls. 31293647 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE In this review, we discuss the underlying mechanisms through which ROS1 tumor cells acquire resistance to crizotinib-the first-line drug for ROS1-positive NSCLC, and summarize various new potent drugs which can overcome this resistance and serve as viable alternatives. 31256210 2019
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.400 Biomarker disease BEFREE C-ros oncogene 1 receptor tyrosine kinase (<i>ROS1</i>) rearrangement forms a novel molecular subgroup of non-small cell lung cancer (NSCLC). 30867785 2019